TRCT
BOLT icon

Tower Research Capital (TRC)’s Bolt Biotherapeutics BOLT Stock Holding History

Tower Research Capital (TRC)’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.58K Buy
1,710
+617
+56% +$2.9K ﹤0.01% 4200
2026
Q1 		$4.42K Buy
1,093
+370
+51% +$1.93K ﹤0.01% 4200
2025
Q4 		$3.95K Buy
723
+464
+179% +$2.49K ﹤0.01% 4286
2025
Q3 		$1.38K Sell
259
-136
-34% -$754 ﹤0.01% 4806
2025
Q2 		$2.28K Sell
395
-39
-9% -$258 ﹤0.01% 4673
2025
Q1 		$3.48K Buy
434
+234
+117% +$2.25K ﹤0.01% 4403
2024
Q4 		$2.14K Buy
200
+191
+2,122% +$2.31K ﹤0.01% 4897
2024
Q3 		$119 Hold
9
– – ﹤0.01% 5487
2024
Q2 		$138 Sell
9
-268
-97% -$5.29K ﹤0.01% 5453
2024
Q1 		$7.76K Sell
277
-135
-33% -$3.13K ﹤0.01% 4145
2023
Q4 		$9.22K Buy
+412
New +$8.02K ﹤0.01% 4421
2023
Q3 		– Sell
-33
Closed -$835 – 5957
2023
Q2 		$835 Sell
33
-166
-83% -$5.27K ﹤0.01% 5533
2023
Q1 		$5K Buy
199
+88
+79% +$2.58K ﹤0.01% 4933
2022
Q4 		$3K Sell
111
-816
-88% -$22.4K ﹤0.01% 5153
2022
Q3 		$28K Buy
927
+525
+131% +$21.7K ﹤0.01% 3648
2022
Q2 		$16K Buy
402
+98
+32% +$3.81K ﹤0.01% 4000
2022
Q1 		$17K Buy
304
+89
+41% +$5.99K ﹤0.01% 3675
2021
Q4 		$21K Buy
215
+181
+532% +$34.4K ﹤0.01% 3590
2021
Q3 		$9K Sell
34
-47
-58% -$13.3K ﹤0.01% 4410
2021
Q2 		$25K Buy
81
+28
+53% +$11.4K ﹤0.01% 3669
2021
Q1 		$35K Buy
+53
New +$34.5K ﹤0.01% 3414

Other funds holding BOLT

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tower Research Capital (TRC)'s BOLT Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Bolt Biotherapeutics (BOLT) stake by 56% in Q2 2026, buying an estimated $2.9K and bringing the position to 1,710 shares worth $6.58K. The position accounts for ﹤0.01% of the portfolio, ranked #4200.

Tower Research Capital (TRC) first reported a position in BOLT in Q1 2021 and has held it in 21 quarters since. The position peaked at $35K in Q1 2021. 19 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

  • Tower Research Capital (TRC) held 1,710 shares of Bolt Biotherapeutics worth $6.58K as of Q2 2026.
  • Tower Research Capital (TRC) bought 617 Bolt Biotherapeutics shares in Q2 2026, an estimated $2.9K.
  • Bolt Biotherapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4200 holding.
  • Tower Research Capital (TRC) first reported a position in Bolt Biotherapeutics in Q1 2021 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Bolt Biotherapeutics position peaked at $35K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.